Alembic Pharmaceuticals Limited is reshaping its leadership with the appointment of Chirayu Amin as Executive Chairman, effective April 1, 2026, for a five-year term. The move follows the shareholders’ approval at the company’s 15th Annual General Meeting held on August 5, 2025, and marks a formal transition as the leadership table shifts within the same organizational core. Amin’s new role comes as he completes his tenure as Chief Executive Officer, relinquishing the CEO position on March 31, 2026, ahead of this elevated chairmanship.
Amin brings a track record of growth and strategic direction to Alembic’s boardroom. His academic credentials include a B.Sc. from Maharaja Sayajirao University of Baroda and an MBA from Seton Hall University in New Jersey. Under his leadership, Alembic has pursued growth and innovation, and the company frames his continued association as a stabilizing influence for the long-term strategy and execution roadmap ahead. Beyond corporate leadership, his commitment to social initiatives through various philanthropic endeavors is highlighted in the company’s profile of his wide-ranging community involvement.
The appointment underscores a family-linked yet governance-forward dynamic at Alembic. Amin is the father of Pranav Amin and Shaunak Amin, who serve as Managing Directors of the company, a relationship the board notes with transparency as part of its leadership narrative. In its disclosures, Alembic confirms Amin’s continued active role while clarifying that he is not debarred from office by SEBI or other authorities, signaling a governance stance that aims to balance continuity with oversight.
This leadership transition positions Alembic to pursue its long-term growth and innovation agenda with a steady hand at the helm. By elevating the Executive Chairman role, the company signals a strategic emphasis on sustained vision and governance backing to navigate a competitive pharmaceutical landscape.